LP
PLRX icon

LMR Partners’s Pliant Therapeutics PLRX Stock Holding History

LMR Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,610
Closed -$947K – 1064
2023
Q1 		$947K Buy
35,610
+13,778
+63% +$392K 0.01% 610
2022
Q4 		$422K Buy
+21,832
New +$456K 0.01% 900

Other funds holding PLRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

LMR Partners's PLRX Position: Q2 2023 in Review

LMR Partners sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 35,610 shares — an estimated $947K sold.

LMR Partners first reported a position in PLRX in Q4 2022 and held it in 2 quarters. The position peaked at $947K in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • LMR Partners reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 35,610 Pliant Therapeutics shares in Q2 2023, an estimated $947K.
  • LMR Partners first reported a position in Pliant Therapeutics in Q4 2022 and held it in 2 quarters.
  • LMR Partners's Pliant Therapeutics position peaked at $947K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.